As of 2025-07-02, the Intrinsic Value of Kinnate Biopharma Inc (KNTE) is -11.94 USD. This KNTE valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.65 USD, the upside of Kinnate Biopharma Inc is -550.59%.
Based on its market price of 2.65 USD and our intrinsic valuation, Kinnate Biopharma Inc (KNTE) is overvalued by 550.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.94 - -11.94 | -11.94 | -550.59% |
| P/E | (31.28) - (60.42) | (48.72) | -1938.4% |
| DDM - Stable | (12.47) - (28.99) | (20.73) | -882.2% |
| DDM - Multi | (9.66) - (18.28) | (12.72) | -580.1% |
| Market Cap (mil) | 125.00 |
| Beta | 3.98 |
| Outstanding shares (mil) | 47.17 |
| Enterprise Value (mil) | 68.00 |
| Market risk premium | 4.60% |
| Cost of Equity | 14.41% |
| Cost of Debt | 5.00% |
| WACC | 9.04% |